Clarivate Plc Clarivate (CLVT) is making a big move to simplify its business and lighten its debt load. The company announced a $600 million deal to sell its Life Sciences & Healthcare (LS&H) segment to Altaris LLC, and investors are cheering the news. Shares surged 16.67% in Thursday's regular session and were up another 1.18% in premarket trading Monday.
The divestiture is a strategic shift for Clarivate, which will now focus on its Academia & Government and Intellectual Property businesses. The company says the sale will improve its financial profile, reduce capital intensity, and expand adjusted EBITDA margins. In other words, Clarivate is getting leaner and meaner.
The Deal Details
Here's how the $600 million breaks down: Clarivate will receive $500 million in cash at closing, $25 million after completing a transition services agreement, and a $75 million seller note. The cash proceeds are earmarked for debt reduction, which should please bondholders and equity investors alike.
Clarivate reaffirmed its full-year 2026 financial outlook, including LS&H results. The company expects to classify LS&H as discontinued operations starting in the third quarter and will update its full-year outlook after the deal closes. There's also a non-cash goodwill impairment of $225 million to $250 million tied to LS&H, but Clarivate says that won't affect the financial metrics in its outlook.
A Sharper Focus
After the deal closes, Clarivate will operate as a subscription-first provider of intelligence solutions, workflow software, and tech-enabled services. The remaining business will center on Academia & Government and Intellectual Property. CFO Jonathan Collins summed it up nicely: "This strategic divestiture strengthens Clarivate's financial profile and accelerates our debt reduction plan. Moreover, monetizing the LS&H segment will enhance the quality of our revenue mix, lower capital intensity, and improve margins. The result is a streamlined Company with increased financial flexibility to support long-term growth and disciplined capital allocation."
What Analysts Think
Wall Street is cautiously optimistic. The stock carries a Hold rating with an average price target of $2.95. Recent analyst moves include Citigroup (Neutral, target lowered to $2.80 on March 4), Barclays (Underweight, target lowered to $2.40 on February 25), and RBC Capital (Sector Perform, target lowered to $3.00 on February 25). With the stock trading around $2.62 in premarket, there's some upside if the company executes well.
Clarivate's price action reflects investor optimism that the sale will unlock value and strengthen the balance sheet. The company is betting that a focused strategy will lead to better growth and margins. Time will tell if that bet pays off, but for now, the market is giving Clarivate a thumbs up.
